Armata Pharmaceuticals (ARMP) Non-Current Assets (2013 - 2026)

Armata Pharmaceuticals (ARMP) has 14 years of Non-Current Assets data on file, last reported at $63.9 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 13.81% year-over-year to $63.9 million; the trailing twelve-month figure through Mar 2026 stood at $275.9 million (down 8.78% YoY), and the FY2025 full-year result was $66.2 million, down 11.87% from the prior year.
• Non-Current Assets eased to $63.9 million in Q1 2026, from $66.2 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $79.2 million in Q4 2023 to a low of $59.1 million in Q1 2022.
• A 5-year average of $70.8 million and a median of $73.3 million in 2025 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets surged 109.3% in 2022 and declined 13.81% in 2026, its largest moves.
• Tracing ARMP's Non-Current Assets over 5 years: stood at $68.8 million in 2022, then grew by 15.16% to $79.2 million in 2023, then dropped by 5.15% to $75.1 million in 2024, then dropped by 11.87% to $66.2 million in 2025, then retreated by 3.56% to $63.9 million in 2026.
• Business Quant data shows ARMP's Non-Current Assets at $63.9 million in Q1 2026, $66.2 million in Q4 2025, and $72.6 million in Q3 2025.